Opus Genetics to Participate in Leading Medical Conferences in May 2026

Rhea-AI Summary

Opus Genetics (Nasdaq: IRD) announced that leadership will present program updates at multiple ophthalmology and gene‑therapy conferences in May 2026, including ARVO (May 3–7), ASGCT (May 11–15), Retina World Congress (May 14–17) and the Retinal Therapeutics Innovation Summit (May 1).

Presentations will cover preliminary Phase 1b/2a OPGx-BEST1 clinical data, preclinical OPGx-RHO work, and translational assays advancing their inherited retinal disease pipeline.

Argus Apr 27 session

-2.10% close to close 1.1x rel. volume Open Argus

Details

News Market Reaction – IRD

On Apr 27, the day this news came out, IRD closed 2.10% below the previous close.

Data tracked by StockTitan Argus for the Apr 27 session.

Key Figures

Financing facility size: $155 million Initial tranche: $35 million Pro forma cash: $100 million +5 more

Financing facility size

$155 million

Strategic Oberland Capital facility (up to amount available)

Initial tranche

$35 million

First funding tranche under Oberland facility

Pro forma cash

$100 million

Estimated cash after financing, extending runway into 2029

Year-end cash

$45.1M

Cash balance at end of 2025

BCVA improvement

12-letter gain

Early OPGx-BEST1 safety and efficacy signal

CST reduction

23% reduction

Early OPGx-BEST1 efficacy metric

PDUFA date

Oct 17, 2026

Phentolamine sNDA review timeline

Registered resale shares

7,374,632 shares

Common stock issuable from Series B Non‑Voting Convertible Preferred

Historical Context

5 past events · Latest: Apr 10

5 events

1. Apr 10

   Clinical data presentations

   24h Move

   -2.5%

   Announced ASCRS presentations including full Phase 3 VEGA-3 results and analyses.

2. Apr 06

   Strategic financing

   24h Move

   +1.3%

   Secured up to $155M primarily non-dilutive capital and extended cash runway.

3. Mar 24

   Industry recognition

   24h Move

   -1.7%

   Named to Fast Company’s World’s Most Innovative Companies 2026 list in Biotech.

4. Mar 10

   Earnings and update

   24h Move

   +1.7%

   Reported 2025 results, cash position, and progress across OPGx-BEST1 and LCA5.

5. Mar 03

   Investor conferences

   24h Move

   -1.9%

   Outlined March 2026 investor conference participation and webcast availability.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

phase 1b/2a, gene therapies, subretinal injection, tRNA, +1 more

5 terms

phase 1b/2a medical

"previously disclosed preliminary data from our ongoing Phase 1b/2a OPGx-BEST1 study"

Phase 1b/2a is a combined early-stage clinical study that first tests safety and optimal dosing in a small group and then expands to look for initial signs that the drug works in the target patients. Think of it as a prototype test followed by a small pilot run: it helps companies decide whether to invest in larger, more expensive trials. Investors watch these results because they reduce scientific uncertainty and can sharply affect a drug’s value and development timeline.

gene therapies medical

"a clinical-stage biopharmaceutical company developing gene therapies to restore vision"

Gene therapies are medical treatments that change or replace a person’s genetic instructions to fix or counteract a disease, using biological delivery methods to get the new material into cells — like repairing or swapping pages in a faulty instruction manual. They matter to investors because they can offer one-time or long-lasting cures with large market potential, but carry high development costs, regulatory scrutiny and manufacturing challenges that make outcomes binary and investment risky.

subretinal injection medical

"OPGx-RHO (scAAV2/5-RHO820-shRNA820) Delivered by Subretinal Injection in a Canine Model"

A subretinal injection is a medical procedure that places a drug, gene therapy, or cells directly into the thin space beneath the retina at the back of the eye, delivering treatment precisely where damaged vision cells live. For investors, it matters because this targeted approach can increase effectiveness but also raises surgical complexity, regulatory hurdles, costs and safety considerations that affect clinical success, commercialization timeline and market adoption—think of burying fertilizer under a lawn rather than sprinkling it on top.

tRNA medical

"Therapeutic Platform for BEST-1-associated Blindness: Anticodon-Engineered tRNA and Gene Augmentation"

Transfer RNA (tRNA) is a small molecule in cells that carries building blocks called amino acids to the protein-making machinery, matching them to the instructions encoded in messenger RNA much like a delivery truck that reads an address on a package and drops off the right part. For investors, tRNA is important because it underlies how many biotech drugs, genetic tests, and manufacturing processes work; changes or innovations involving tRNA can affect a company’s research progress, regulatory approval prospects, and commercial potential.

scAAV2/5 medical

"Nonclinical Efficacy and Toxicity Study of GMP-grade Vector OPGx-RHO (scAAV2/5-RHO820-shRNA820)"

scaav2/5 is an engineered gene‑therapy delivery vehicle built from a modified adeno‑associated virus that combines characteristics of two viral variants (2 and 5) and uses a self‑complementary genome to start producing the therapeutic gene faster. Think of it as a specialized mailing system that aims to deliver genetic instructions more quickly and efficiently to target cells. For investors, the vector choice affects how well a therapy works, how safe and scalable it is to manufacture, and therefore the clinical and commercial risk and upside.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RESEARCH TRIANGLE PARK, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics (Nasdaq: IRD) (“Opus Genetics” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs), today announced that members of its leadership team will participate in several leading ophthalmology and industry conferences.

“We look forward to sharing progress across our programs at ARVO and other leading meetings this May, including encouraging findings from our LCA5 and BEST1 gene therapy programs,” said Dr. George Magrath, Chief Executive Officer, Opus Genetics. “At ARVO, we will present previously disclosed preliminary data from our ongoing Phase 1b/2a OPGx-BEST1 study, alongside new preclinical and translational work advancing our pipeline. These meetings provide an important opportunity to engage with the ophthalmology community as we work to develop durable, one-time treatments for inherited retinal diseases.”

Retinal Therapeutics Innovation Summit 2026

• Presentation Title: Safety and Efficacy of OPGx-RHO Silence-and-Replace Gene Therapy for RHO-adRP: Evidence Across Two Large Animal Models
• Date: May 1, 2026
• Location: Denver, CO
  
  

Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

• Presentation Title:
  • Restoration of Cone-Mediated Vision After Gene Augmentation in Children with LCA5
  • Preliminary Results from Adult Participants in a Phase 1b/2a Clinical Study of OPGx-BEST1 Gene Therapy for ARB and BVMD due to BEST1 Mutations
  • Development of Cell-Based Expression and Functional Potency Assays for OPGx-BEST1 Gene Therapy
• Date: May 3–7, 2026
• Location: Denver, CO
  
  

American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

• Presentation Title:
  • Therapeutic Platform for BEST-1-associated Blindness: Anticodon-Engineered tRNA and Gene Augmentation
  • Nonclinical Efficacy and Toxicity Study of GMP-grade Vector OPGx-RHO (scAAV2/5-RHO820-shRNA820) Delivered by Subretinal Injection in a Canine Model of RHO-adRP
• Date: May 11–15, 2026
• Location: Boston, MA
  
  

Retina World Congress

• Presentation Title: Retina Unplugged: Inherited and Rare Retinal Diseases
• Date: May 14–17, 2026
• Location: Fort Lauderdale, FL
  
  

About Opus Genetics
Opus Genetics is a clinical-stage biopharmaceutical company developing gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs). The Company is developing durable, one-time treatments designed to address the underlying genetic causes of severe retinal disorders. The Company’s pipeline includes seven AAV-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. Opus Genetics is also advancing a small-molecule therapy, Phentolamine Ophthalmic Solution 0.75%, beyond its approved use for pharmacologically induced mydriasis, with a supplemental new drug application under review for presbyopia and an ongoing Phase 3 pivotal trial for mesopic, low contrast conditions after keratorefractive surgery (dim light disturbances). The Company is based in Research Triangle Park, NC. For more information, visit www.opusgtx.com.

Contacts:

Investors
Jenny Kobin
Remy Bernarda
IR Advisory Solutions
ir@opusgtx.com

Media
Kimberly Ha
KKH Advisors
917-291-5744
kimberly.ha@kkhadvisors.com

Source: Opus Genetics

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Opus Genetics (IRD) present at ARVO May 3–7, 2026?

Opus Genetics will present preliminary Phase 1b/2a OPGx-BEST1 clinical data and new preclinical/translational work. According to the company, presentations include restoration of cone-mediated vision, adult preliminary OPGx-BEST1 results, and cell-based expression and potency assay development.

When and where is Opus Genetics presenting OPGx-RHO data in May 2026?

Opus Genetics will present OPGx-RHO nonclinical efficacy and toxicity data at ASGCT, May 11–15, 2026 in Boston. According to the company, the study uses GMP-grade OPGx-RHO delivered by subretinal injection in a canine RHO-adRP model.

What findings will Opus Genetics share about BEST1 programs at May 2026 meetings?

Opus Genetics will share preliminary OPGx-BEST1 clinical results and platform work at multiple May meetings. According to the company, content includes adult preliminary Phase 1b/2a data, gene augmentation approaches, and anticodon-engineered tRNA strategies for BEST1-associated blindness.

Which Opus Genetics presentation is scheduled for the Retinal Therapeutics Innovation Summit on May 1, 2026?

Opus Genetics will present on safety and efficacy of OPGx-RHO silence-and-replace gene therapy across two large animal models on May 1, 2026 in Denver. According to the company, the talk focuses on evidence supporting RHO-adRP therapeutic development.

How can investors follow Opus Genetics (IRD) updates from the May 2026 conferences?

Investors can follow conference presentations and industry coverage for timing and abstracts during May 2026. According to the company, leadership will present at ARVO, ASGCT, Retina World Congress, and the Retinal Therapeutics Innovation Summit with program-specific sessions noted above.